Questor is The Telegraph’s stockpicking column, helping you decode the markets and offering insights on where to invest for ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic disorder X-linked adrenoleukodystrophy, or X-ALD.

Allurion has added more efficacy and safety data to support its intragastric balloon, but popularity of GLP-1 drugs shows no ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Novo Nordisk AS (NVO) reports a 25% sales increase, upgrades its full-year outlook, and addresses challenges in the insulin ...

A CNBC investigation into counterfeit weight-loss drugs revealed an international illegal marketplace where criminals either alter the drugs or ship the real product from overseas.

Shares of WeightWatchers parent company WW International ($WW) have rocketed 40% higher on news that the company plans to ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...